The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.